Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention
of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific
antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
Active, not recruitingCTIS2023-506578-11-00
Janssen - Cilag InternationalEGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
Start: 2023-04-25Target: 60Updated: 2025-11-07